I believe if the OnCarylytics/Blincyto combo trial works, then there is no way Amgen is going to leave it at that. That would indeed open up the 90% solid tumor market to them. The data just need to be compelling and Amgen would act. And since OnCarlytics/Blincyto is the first mover, all the more Amgen will want to get a wiggle on to be first in class.
IMU Price at posting:
10.5¢ Sentiment: Buy Disclosure: Held
